Tactiva Therapeutics

Tactiva Therapeutics is a next generation adaptive cell therapy (ACT) company that is developing a TCR (T-cell receptor) therapy which uniquely combines CD4 and CD8 systems in order to produce a more clinically relevant therapeutic. The technology was developed at Roswell Park Cancer Institute in Buffalo, NY. The T cells derive from a patient’s own cells and are re-programmed to recognize, attack and destroy cancer cells and have been shown to enhance response to clinical treatment.